Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition
Mérédis Favreau,
Koen Venken,
Sylvia Faict,
Ken Maes,
Kim De Veirman,
Elke De Bruyne,
Xavier Leleu,
Louis Boon,
Dirk Elewaut,
Karin Vanderkerken,
Eline Menu
Affiliations
Mérédis Favreau
Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Belgium;Department of Rheumatology, Ghent University Hospital, Belgium;Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center, Ghent University, Belgium
Koen Venken
Department of Rheumatology, Ghent University Hospital, Belgium;Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center, Ghent University, Belgium
Sylvia Faict
Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Belgium
Ken Maes
Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Belgium
Kim De Veirman
Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Belgium
Elke De Bruyne
Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Belgium
Xavier Leleu
Service d’Hématologie et Thérapie Cellulaire, Pôle Régional de Cancérologie, Hopital de la Miléterie, 86021 Poitiers, France
Louis Boon
Bioceros, Utrecht, The Netherlands
Dirk Elewaut
Department of Rheumatology, Ghent University Hospital, Belgium;Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center, Ghent University, Belgium
Karin Vanderkerken
Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Belgium
Eline Menu
Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Belgium
